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length-of-stay was 15.8 days (15.0 days for DVT patients and 17.0 days for PE pa-
tients). The mean total cost was Chinese Yuan (CNY) 16487.91 (median:9039.10,
IQR:5128.80-18981.83), CNY 17698.61 (median:8643.68, IQR:5025.03-19594.93) in pa-
tients with DVT and CNY 14523.39 (median:9879.25, IQR:5870.43 -ee18630.41) in
patients with PE. The average drug cost accounts for 47.4% of the total cost (mean:
6340.29; median:4479.94, IQR:2279.88-7991.12).The multiple linear regressions
showed that patients from tertiary hospitals had 105% higher costs than those
from primary hospitals (P  0.001), and patients from municipalities had 48.6%
higher costs than those from prefecture-level cities (P 0.01). CONCLUSIONS: The
costs per hospitalization associated with DVT or PE events are substantial. Hospi-
talization costs are now driven predominantly by the cost of drugs, levels of hos-
pitals and cities.
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HOSPITAL BASED COST SURVEY OF ACUTE CORONARY SYNDROME IN SOUTH
KOREA
Kim BRM
Seoul National University, Seoul, Seoul, South Korea
OBJECTIVES: Acute coronary syndromes (ACS) consist mainly of ST-segment ele-
vation myocardial infarction (STEMI) and unstable angina (UA)/non-STEMI
(NSTEMI). ACS showed an enormous medical, social, and economic burden world-
wide. ACS in the form of myocardial infarction is responsible for almost half of all
deaths related to cardiovascular disease. South Korea compared to the OECD coun-
try average, shows high cardiovascular morbidity and mortality, and the recur-
rence rate is increasing every year. We examined the direct cost of hospitalization
for ACS which planned percutaneous coronary intervention (PCI) using medical
cost survey in South Korea.METHODS:We conducted a cost survey to examine the
actual direct medical costs of the team of cardiologists, technicians of intervention
and reimbursement reviewers in the hospital. To examine the cost data of a pa-
tients who received procedures, operations and admissions. We could select index
patient cases through medical chart review as he/she had ever been visited the
hospital since last 1 year. Through delphi panel discussion and reviewing, we
refined the cost data excluding non-related ACS treatment in index case. RESULTS:
It is the first survey of the actual cost in ACS. The totalmedical cost for ACS patients
who have undergone the procedure was 4.451 million Korean won. The cost is
lower level if considering difficulties in surgery. But among the components in ACS,
the cost of stents and devices were largely accounted for the total cost.
CONCLUSIONS: The medical cost of ACS in Korea is a burden to both patients and
society, due to increasing recurrence in cardiovascular disease. Among the total
cost, the cost of stents is higher than the inpatient cost. This is one of the reasons
of the highmedical cost in ACS. This result will have as implication the adjustment
of the cost of stents and devices in ACS treatment in South Korea.
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OBJECTIVES: Stroke is amajor cause of death around the world. This study aims to
evaluate the quality of care in pharmacist’s participation in a multidisciplinary
ischemic stroke team, and the potential cost avoidance associatedwith the recom-
mendations made by clinical pharmacists.METHODS:We conduct a retrospective
study at a stroke center with pharmacist participation in medical rounds. Six hun-
dred and forty-eight patients who suffered with stroke attack 10 days before ad-
mission are enrolled into sample. Data collects from November 2008 to September
2010. The patients with hemorrhage stroke are excluded from sample. Quality of
acute stroke care is assessed by five pharmaceutical care-related performance in-
dicators according to American Heart Association/American Stroke Association
Get With the Guidelines-Stroke program (GWTG-Stroke). The cost avoidance is
measured by the scored probability of harm. RESULTS: Study results show that
there is significantly improved in four performance indicators in the year of 2010
and 2008. Indicators with significant improvement include intravenous thrombo-
lytic (24.00% vs. 00.00%), early and discharge antithrombotic (95.93% vs. 93.33%,
96.56% vs. 93.18%), and anticoagulation for atrial fibrillation (71.43% vs. 20.00%).
The indicator of prescribing rate of lipid-lowing medications, however, remains
stable over two separate periods (51.70% versus 52.70%) due to the restriction of the
National Health Insurance Policy. The assumption that cost of prolonged length of
hospital stay due to ADE is about $5000 NTD. Therefore, cost avoidance was NT
$2,207,816 NTD in this study. CONCLUSIONS: This study demonstrates that phar-
macists involvement in a multidisciplinary ischemic stroke team are associated
with facilitating the quality of care and increasing potential cost avoidance.
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OBJECTIVES: To evaluate cost-effectiveness of adding ezetimibe to simvastatin
versus a switch to rosuvastatin or atorvastatin for high CHD risk patients who
cannot attain treatment goal (LDL-C  100 mg/dL) on their current simvastatin
dosage from Thai payer perspective.METHODS: A published Markov model (Cook
et al. 2004) was used to project lifetime costs and outcomes of lipid-lowering treat-
ment in primary and secondary CHD prevention. Lipid efficacy data were obtained
from clinical trials. Risks of CHD events and non CHD-related mortality rates were
estimated by using Framingham Heart Study risk equations and information from
Ministry of Public Health (MOPH), respectively. Disease-related costswere obtained
from published local studies. Drug prices were those published by MOPH. All costs
were expressed in THB 2010 values. Future costs and outcomes were discounted at
3%. Two scenarios were compared in the analysis: the addition of ezetimibe to
simvastatin 20 mg versus switching to rosuvastatin 10 mg and the addition of
ezetimibe to simvastatin 40 mg versus switching to atorvastatin 40 mg. RESULTS:
Ezetimibe co-administration increased life expectancy (LY) by 0.15 and 0.26 years
and resulted in 0.07 and 0.12 additional quality-adjusted life years (QALY) when
compared to a switch to rosuvastatin and a switch to atorvastatin, respectively.
The QALY gained would yield lifetime cost-savings of Baht 1,106 and 2,137 per
patient for such comparisons. Similar results were obtained where costs and out-
comes were either discounted or undiscounted. The sensitivity analyses showed
that results were robust to changes across scenarios. CONCLUSIONS: This analysis
suggested that addition of ezetimibe to simvastatin is the dominant treatment
strategy (more effective and less costly) in both scenarios. The results are very
imperative to assist policy decision-making in order to increase access to second-
line treatment option for patients not achieving lipid treatment goals with simva-
statin monotherapy in Thailand.
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TRANS-RADIAL PERCUTANEOUS CORONARY INTERVENTION
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OBJECTIVES: In response to TW-DRG implementation, based on safety, through
the radial artery cardiac catheterization intervention, how to make patients dis-
charged earlier, save health care costs and create a win-win between patients and
hospitals.METHODS: In this retrospective study in Han-Ming Hospital, Taiwan, we
enrolled 282 cases from January 1, 2006 to December 31, 2010. RESULTS: In the
admission less than 24 hours after the PCI treatment, there were 129 males and 51
females (64.312.5 years, mean s.d.). Besides, in other group over 24 hours, there
were 74 males and 28 females (69.111.5 years). Using Logistic Regression Analysis,
age65 years (RR 1.683, 95%CI 1.943-3.031, p-value 0.010,OR: 2.647,95%CI: 1.009-6.941,
p-value 0.030)eATroponin-I 1 ug/L(RR 1.963, 95%CI 1.254-15.155, p-value 0.001,OR:
2.053, 95%CI: 1.240-17.601, p-value 0.004)eAlesion numbers 2(RR 1.402, 95%CI 1.330-
5.955, p-value 0.001,OR:1.128, 95%CI: 1.120-10.617, p-value 0.008)eATreatments using
stents (RR 1.963, 95%CI 1.254-15.155, p-value 0.018,OR: 4.688, 95%CI:1.443-15.232, p-
value 0.033)eAvascular type such as A & B1 (RR 1.683, 95%CI 1.037-2.731, p-value
0.017,OR: 2.569, 95%CI: 1.751-8.794, p-value 0.036)eAnon-complication (RR 2.153,
95%CI 1.979-4.473, p-value 0.039,OR: 3.891, 95%CI: 1.011-25.801, p-value 0.043).
CONCLUSIONS: If patients have characteristics like age 65 years, Troponin-I 1
ug/L, lesion numbers less than 2, using stents, vascular type diagnosed as A and B1,
and non-complication, they could tend to discharge in 24 hours after PCI treat-
ment.
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OBJECTIVES: To conduct a pharmacoeconomic assessment of thrombolysis by in-
travenous recombinant tissue plasminogen activator (rt-PA) therapy for acute isch-
emic stroke (AIS) in a tertiary hospital in China.METHODS:A retrospective analysis
was conducted usingmedical records data among patients hospitalized for AIS and
receiving rt-PA therapy (time window: 6 hours after AIS) from September 2007 to
September 2008. A conservative therapy group (including antiplatelet, anticoagu-
lation, statin, traditional Chinesemedicine) werematched (1:1) on age, gender, risk
factors (hypertension, diabetes, previous stroke/TIA, high cholesterol/lipids and
coronary heart disease), Glasgow Coma Scale (GCS) and National Institutes of
Health Stroke Scale (NIHSS). Two groups were compared on 14th-day clinical out-
comes, utilities estimated from modified Rankin Scale (mRS) scores, and costs.
RESULTS: Forty patients (65%male, age 6511 years) in rt-PA and 40 patients (58%
male, age 6911 years) in conservative group were included. No differences were
found in mortality between 2 groups. Among survivors on 14th day, NIHSS
(meanSD: 1.892.64 vs. 4.385.57; P0.018 and mRS (0.771.26 vs. 1.921.80;
P0.002) were lower in rt-PA (N37) than conservative group (N39). Barth Index
(BI) was higher in rt-PA group (90.5716.71 vs. 74.3625.88; P0.002). Hospital
length-of-stay (LOS) was shorter in rt-PA (15.47.8 days) than conservative group
(19.28.80 days; P0.05). Total costs were not significantly different:
¥22,82611,049 (rt-PA) vs. ¥18,60510,713 (conservative), while total drug costs
were higher in rt-PA (¥13,3794,765) than conservative group (¥10,2256,222)
(P0.017). No difference was found in cost of hospital care (¥2,5742,608 vs.
¥2,2752,723), laboratory exam (¥1,8541,037 vs. ¥1,867974), etiology exam
(¥2,335823 vs. ¥2,1251,156) and traditional Chinese medicine (¥354266 vs.
¥278266) between rt-PA and conservative group. Utility gained with rt-PA was
0.04 (0.61 vs. 0.57). CONCLUSIONS: Intravenous rt-PA was associated with lower
patients’ disabilities, less hospital days, and comparable total costs compared to
conservative therapy for the management of AIS in this study population.
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LIFETIME COST-EFFECTIVENESS ANALYSIS OF TICAGRELOR IN PATIENTS
WITH ACUTE CORONARY SYNDROMES BASED ON THE PLATO TRIAL: A
SINGAPORE HEALTH CARE PERSPECTIVE
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